Core Viewpoint - Eli Lilly (LLY.US) has reached a significant agreement with the U.S. government to lower the price of its GLP-1 drugs to $245 per month in exchange for federal Medicare coverage, potentially opening a new market of approximately 30 million people, with an annual sales potential of $27 billion [1] Group 1 - Eli Lilly's stock rose nearly 2% on Wednesday, continuing to set historical highs, with a cumulative increase of 16% for the month [1] - Citigroup has raised its price target for Eli Lilly from $1,250 to $1,500, enhancing market recognition of the company's value [1]